Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CANF
CANF
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CANF News
UiPath to Join S&P Midcap 400 Index Effective January 2, 2026
Dec 27 2025
Yahoo Finance
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
Dec 26 2025
Benzinga
Can-Fite BioPharma Secures Patent in Brazil for A3AR Agonist in Sexual Dysfunction Treatment
Dec 26 2025
NASDAQ.COM
Can-Fite Secures Brazilian Patent for Sexual Dysfunction Drug
Dec 26 2025
Globenewswire
Can-Fite Secures Brazilian Patent for A3AR Agonist in Sexual Dysfunction Treatment
Dec 26 2025
Newsfilter
Multi Ways Holdings Reports 87.65% Revenue Growth to $26.44 Million in H1 2025
Dec 24 2025
Benzinga
UiPath to Replace Synovus in S&P MidCap 400 Effective January 2, 2026
Dec 24 2025
Benzinga
Can-Fite BioPharma Approves 1-for-3,000 Reverse Split Following Shareholder Approval
Dec 23 2025
Globenewswire
Can-Fite BioPharma Authorizes 1-for-3,000 Reverse Stock Split; Shares Decline
Dec 23 2025
SeekingAlpha
Can-Fite Advances Namodenoson Clinical Trials, Interim Data Expected Q4 2026
Dec 16 2025
Newsfilter
Can-Fite BioPharma CEO to Present Drug Developments at NobleCon21 on December 3
Nov 26 2025
Globenewswire
D. Boral Capital Reiterates Buy Rating on Can Fite Biofarma with $11 Price Target Intact
Nov 18 2025
Benzinga
Tuesday's Major Stock Market Highlights: Morning News Summary!
Nov 18 2025
TipRanks
Dow Drops More Than 300 Points as Home Depot Reports Disappointing Earnings
Nov 18 2025
Benzinga
What’s Driving the Increase in Can-Fite BioPharma Stock (CANF) Today?
Nov 18 2025
TipRanks
Can-Fite BioPharma - Price Target for Depositary Receipt (CANF) Reduced by 10.95% to 4.19
Nov 09 2025
NASDAQ.COM
Show More News
